Prevention Is the Best Treatment: The Case for Understanding the Transition from Monoclonal Gammopathy of Undetermined Significance to Myeloma

International Journal of Molecular Sciences

Qian Xiao¹  Vanessa De Oliveira²  Mahmoud Ali²  Fenghuang Zhan²  Yogesh Jethava²  MichaelH. Tomasson²  AdamM. Fitzsimmons³  MelissaL. Bates⁴ 

[1] Department of Health Human Physiology, University of Iowa, Iowa City, IA 52242, USA;Department of Internal Medicine, Hematology, Oncology, and Bone Marrow Transplant Division, University of Iowa, Iowa City, IA 52242, USA;Graduate Program in Molecular Medicine, University of Iowa, Iowa City, IA 52242, USA;Holden Comprehensive Cancer Center, University of Iowa, Iowa City, IA 52242, USA;

关键词: multiple myeloma;    prevention;    monoclonal gammopathy of undetermined significance;    plasma cell disease;    therapy;   

DOI  :  10.3390/ijms19113621

来源: DOAJ

【 摘 要 】

Multiple myeloma is an invariably fatal cancer of plasma cells. Despite tremendous advances in treatment, this malignancy remains incurable in most individuals. We postulate that strategies aimed at prevention have the potential to be more effective in preventing myeloma-related death than additional pharmaceutical strategies aimed at treating advanced disease. Here, we present a rationale for the development of prevention therapy and highlight potential target areas of study.

【 授权许可】

Unknown